Skip to main content
Journal of Neurotrauma logoLink to Journal of Neurotrauma
. 2020 Aug 14;37(17):1870–1879. doi: 10.1089/neu.2019.6962

Exploring Neuronal Vulnerability to Head Trauma Using a Whole Exome Approach

Omar Ibrahim 1, Heidi G Sutherland 1, Neven Maksemous 1, Robert Smith 1, Larisa M Haupt 1, Lyn R Griffiths 1,
PMCID: PMC7462038  PMID: 32233732

Abstract

Brain injuries are associated with oxidative stress and a need to restore neuronal homeostasis. Mutations in ion channel genes, in particular CACNA1A, have been implicated in familial hemiplegic migraine (FHM) and in the development of concussion-related symptoms in response to trivial head trauma. The aim of this study was to explore the potential role of variants in other ion channel genes in the development of such responses. We conducted whole exome sequencing (WES) on16 individuals who developed a range of neurological and concussion-related symptoms following minor or trivial head injuries. All individuals were initially tested and shown to be negative for mutations in known FHM genes.

Variants identified from the WES results were filtered to identify rare variants (minor allele frequency [MAF] <0.01) in genes related to neural processes as well as genes highly expressed in the brain using a combination of in silico prediction tools (SIFT, PolyPhen, PredictSNP, Mutation Taster, and Mutation Assessor). Rare (MAF <0.001) or novel heterozygous variants in 7 ion channel genes were identified in 37.5% (6/16) of the cases (CACNA1I, CACNA1C, ATP10A, ATP7B, KCNAB1, KCNJ10, and SLC26A4), rare variants in neurotransmitter genes were found in 2 cases (GABRG1 and GRIK1), and rare variants in 3 ubiquitin-related genes identified in 4 cases (SQSTM1, TRIM2, and HECTD1).

In this study, the largest proportion of potentially pathogenic variants in individuals with severe responses to minor head trauma were identified in genes previously implicated in migraine and seizure-related autosomal recessive neurological disorders. Together with results implicating variants in the hemiplegic migraine genes, CACNA1A and ATP1A2, in severe head trauma response, our results support a role for heterozygous deleterious mutations in genes implicated in neurological dysfunction and potentially increasing the risk of poor response to trivial head trauma.

Keywords: concussion, genetics, head trauma, ion channel, neurotransmitters

Introduction

Neuronal and synaptic ion channels, which include calcium, potassium, and sodium channels, ATPase transporters, and solute carriers, control the flow of ions and neurotransmitters through cellular membranes.1 In addition to their normal functions, they are crucial for restoring neuronal homeostasis in the aftermath of a head impact.2 Ion channelopathies, a wide range of dysfunctions related to ion channels and ion transporters, have long been documented as one of the main causes of several neurological disturbances. The calcium channel gene, CACNA1A, has been identified as a key gene in which mutations can cause familial hemiplegic migraine (FHM), along with several other FHM-related ion channel genes (ATP1A2, SCN1A). CACNA1A, which encodes the 1αpre-forming subunit of the Ca2+ voltage-gated Cav2.1 channel, has been shown to harbor mutations implicated in the development of an array of neurological disturbances and concussion-related symptoms (migraine, epilepsy, coma, and cerebral edema) following minor or trivial head trauma.3–5 Recently, mutations in the ATP1A2 gene have also been found to be present in individuals of a large family with an over-representation of concussion incidents.6 Maksemous and colleagues7 additionally recently reported 8 ATP1A2 variants in individuals who show severe responses to trivial head trauma. In addition, head trauma was found to start myriad neurological symptoms in individuals with variants in ABCD1, an X-linked adrenomyeloneuropathy-causing gene, which is implicated in cellular peroxisome functioning.8

These mutations can change the functionality and structure of ion channels, leading to abnormal responses to minor trauma or mild traumatic brain injury (mTBI).9 Additionally, ion channels are suggested to play a role in the development of acquired neurological dysfunction (e.g., epilepsy) following environmental disturbances (e.g., head injury or trauma).10 Further evidence suggests that genotype, particularly of neuronal genes including KIAA0319,11 BDNF,12–14 and APOE15,16 plays a role in response to head injury and recovery from mTBI.

Head injury or impact leads to cellular distortion and changes in membrane permeability, which contributes to an acute imbalance in extracellular ion gradients, in particular, K+, which is expelled into the extracellular space.17,18 Glutamate and other excitatory neurotransmitters are then released by neurons, likely due to the imbalance caused by K+ efflux, paired with Na+ and Ca2+ influx into the neurons, with the resulting ion imbalances contributing to local and downstream neuronal depolarization.19 Cellular-level homeostasis can be re-established through ion pump activation, requiring high adenosine triphosphate (ATP) expenditure and energy, a process that leads to higher neuronal oxidative stress.18 This energy depletion is characterized by hyperglycolysis (an above-average increase in glucose utilization20 and interference of Ca2+ ions with cellular and mitochondrial functioning. The high influx of Ca2+ following a TBI has been linked to long-term neuronal dysfunction,21 leading to an array of symptoms, with headache and migraine being the most common presentation.22

Although mutations in the calcium channel gene (CACNA1A) have been shown to affect neurological response to head trauma in carriers,4,23–25 several cases have occurred of patients presenting with similar reactions to head trauma with no mutations present in CACNA1A. In a cohort of patients referred for FHM genetic testing following severe reactions to trivial head trauma, the majority of individuals were shown to be negative for variants in FHM genes. Post-head injury symptoms include migraine, and cognitive or affective changes.26 However, the current study is focused on somatic rather than cognitive or behavioral symptoms. Based on the crucial role ion channels and neurotransmitters play in response to head trauma, we hypothesize that underlying mutations in ion channel and neurotransmitter genes might be implicated in the development of concussion symptoms following minor head trauma, similar to those observed in CACNA1A and ATP1A2 cases. In this study we investigate the role of rare and functional variants in other ion homeostasis genes in relation to neurological symptoms following minor head trauma.

Methods

Cohort

Over 300 patients have been referred to the Genomics Research Centre (GRC) Diagnostic Clinic for HM diagnostic testing. Twenty-four patients reported episodes of confusional migraine, and other concussion-related symptoms after mild head trauma including loss of consciousness, seizure, amnesia and/or edema noted in their clinical descriptions. Although their presentation was heterogeneous, all individuals were identified to have head trauma or injury prior to the onset of their neurological symptoms. The 24 suspected case patients also had relevant symptoms as described in the International Headache Society (IHS) criteria for HM.

As reported in Maksemous and colleagues,7 8 of the 24 case patients presenting with concussion-related symptoms had likely pathogenic variants in ATP1A2. The remaining 16 individuals had no deleterious or pathogenic mutations in FHM genes, prompting the whole exome sequencing (WES) approach used in this study. Ethical approval was granted for this study with samples obtained through the diagnostic facility of the GRC (Queensland University of Technology [QUT] Approval Number 1400000748). A summary of the clinical notes provided for the16 individuals examined in this study is provided in Table 1.

Table 1.

Clinical Notes for 24 Cases Referred for Diagnostic Testing of Suspected Hemiplegic Migraine with Notable Varied Neurological Dysfunctions after Minor and/or Trivial Head Trauma

Case ID Age Sex Clinical notes
R170 10–18 Male Confusional migraine following minor head injury
R211 10–18 Male Severe migraine and ataxia following head injury
R259 10–18 Female Netball hit to right side of temple. Patient described surroundings going black and then quickly recovering. A soccer game made them more confused and presented to ER with hemiplegia. A background of headaches, unilateral throbbing, which increase upon sitting up, which typically occur in the morning and are a little bit unpredictable. Photophobia, noise sensitivity, and nausea reported. No other neurological phenomena, i.e., aura reported. Both maternal and paternal aunts have bad migraines; however, neither parents nor siblings, nor anyone else in the extended family suffer from migraines.
R117 0–10 Female Recurrent episodes of pallor and vomiting following minor head injuries. Slurred speech with inappropriate words. Mild biparietal headache on most days since the injury; these headaches usually last for several minutes and resolve spontaneously. Consistent noise sensitivity and light sensitivitiy occurred for 3 weeks post-injury. Mother has a history of migraines but there is no other significant family history of neurological problems.
R118 0–10 Male Catastrophic cerebral edema following trivial injury; mother has had hemiplegic migraines.
R197 10–18 Male Migraine on minimal trauma, has two episodes of confusion and headache post rugby games.
R150 0–10 Female Ischaemic stroke after mild head injury.
R171 10–18 Male Acute confusional migraine after head injury.
R120 0–10 Male Severe bleed following suspected minor fall. Only a relatively minor fall, but was followed by malignant cerebral edema and a relatively small subdural bleed with herniation within half an hour of the fall; there is no history or family history of migraine.
R240 10–18 Female Family history of migraine. Netball hit head, lead to headache and confusion.
R110 10–18 Male Repeated attacks of “concussion” after minor head trauma. After minor head trauma he develops a “migraine like” episode with slurred speech, diplopia, headache, and vomiting.
R111 30–50 Male Similar to son, case patient R110.
R167 18–30 Male Head injury induced migraine.
R206 18–30 Male Left-sided numbness following a concussion.
R222 10–18 Male Multiple episodes in a few months of visual disturbance, headache, and vomiting following trivial head trauma, most recently from hitting head against a player's chest at basketball.
R256 10–18 Female An episode of stroke related to minor head trauma, seizure disorder, and episodic ataxia.

DNA preparation and WES

DNA was extracted from blood samples using Qiagen DNeasy kits as per the manufacturer's instructions. Next-generation sequencing (NGS) libraries for WES were constructed using Ion AmpliSeqTM Exome RDY Library Kits (Thermo Fisher Scientific) according to the manufacturer's protocol. The Ion Chef was used to load sample libraries (barcoded fragments of 200 base pairs [bp]) onto P1 chips using Ion P1TM Hi-Q TM Chef Kit protocols. WES was performed on the Ion Proton (Thermo Fisher Scientific) instrument using default settings for Ion AmpliSeq Exome RDY - IC Kit 4x2.

Statistical analysis

Following WES, the Ion Torrent Server was used to generate quality metrics, align reads to the Human Genome 19 (hg19), and the Ion Torrent Variant Caller (TVC) was used to call sequence variants. Whole exomes of the 16 patients negative for HM gene mutations were analyzed for genes implicated in known head-trauma-related conditions, followed by analysis, then all genes related to ion channels, or neuronal functions. Ion Reporter software (version 5.2) was used to explore and filter variants based on minor allele frequency (MAF), gene ontology, and functional scores. A summary of the filtering process and the corresponding genes and variant numbers is provided in Figure 1.

FIG. 1.

FIG. 1.

Variant filtering pipeline to explore relevant variants in patients with severe reaction in trivial head trauma (n = 16) using Ion Reporter software.

In silico prediction tools were then used to investigate the pathogenicity of the mutations. Two sets of tools were used, training-based algorithms (PolyPhen-2 and Mutation Taster) and non-training-based algorithms (SIFT and Mutation Assessor), to avoid results based solely on machine learning tools, which are prone to over-fitting.27,28

Mutation Assessor, an in silico prediction tool based on protein function, was used to explore the potential impact of amino acid (AA) changes on protein structure. Mutation Assessor produces functional impact scores (FI), wherein scores below 0.8 have a neutral impact, scores between 0.8 and 1.9 have a low impact, scores between 1.9 and 3.5 have a medium impact, and scores higher than 3.5 have a high impact.29 PredictSNP is a suitable tool for assessing the potential pathogenicity of variants, as it compiles the data of 8 of the top established prediction models and metrics (MAPP, nsSNPAnalyzer, PANTHER, PhD-SNP, PolyPhen-1, PolyPhen-2, SIFT, and SNAP30) to produce a percentage of predicted deleterious effect or non-pathogenicity as an average of all the tool prediction scores. Whereas PredictSNP incorporates PolyPhen as part of the prediction matrix, the PolyPhen total score is more relevant to this analysis. Consequently, using PolyPhen as a complementary score to SIFT in the first step through Ion Reporter is a stand-alone a priori filtering process that is not related to the overall score of PredictSNP. Mutation Taster, which predicts how potentially disease-causing a variant is,31 was used in conjunction with PredictSNP to establish a more detailed understanding of the effects of certain mutations identified as AA sequence changes, frame shifts, and splice sites.

All reported mutations were confirmed via Sanger Sequencing. Variant relevance was determined based on: 1) biological relevance, such as the expression of the gene in the brain, as determined by the National Center for Biotechnology Information [NCBI] gene database; 2) the limited number of individuals with the variant in other databases such as dbSNP and gnomAD; 3) existing evidence of the involvement of the variant or the gene in a relevant neurological disorder or pathology; and 4) evidence of involvement of the gene in a relevant biological process (i.e., response to concussion or neuroprotective factors).

To increase the robustness of the analysis, the 16 exomes were analyzed using the in-house variant browser pipeline, VCF-DART.32 The pipeline utilizes predetermined gene tiers (see Supplementary Appendix S1) as well as scores from various in silico prediction tools to filter variants of interest. The genes in those tiers were selected from established genetic diagnostic tests for several neurological disorders, with the last tier showing all variants that are not present in previous tiers, thus reducing the likelihood of missing any relevant variants in genes not selected in the tiers. Further, the analysis was conducted with other neurological exomes analyzed from epilepsy, CADASIL syndrome, and mTBI patients with no severe responses to trivial head trauma.

Results

To identify variants in ion-channel and neuronal genes that might be involved in concussion response, WES was performed in 16 individuals who were referred for diagnostic testing after a severe response to a minor head trauma, but for whom no likely pathogenic variants were detected by full exonic sequencing of the known FHM genes. Quality metrics were above the accepted thresholds33 for all samples assayed, as detailed in Table 2. Samples had an average number of reads of 33x106, with a minimum of 21x106 reads. The average mean coverage depth was 99X across all samples, with a minimum coverage depth of 61X. Ion Torrent exome fragments are 200 bp long with an average read length in the samples 111 bp, with a range of 18 and standard deviation (SD) of 5.2, indicating an acceptable level of fragment integrity. Samples had an average of 37,550 called variants and a minimum of 35,600 variants. QC metrics per sample are reported in Table 2.

Table 2.

Quality Metrics of WES by Ion Proton

Case ID Mapped reads (millions) Number of variants Mean read length (bp) Mean depth
R170 22.32 36432 177 61.7
R211 36.67 38092 192 112.9
R259 32.1 37658 190 96.71
R117 37.22 38028 190 111
R118 35.24 37166 188 100
R197 38.27 38119 R111 112.7
R150 21.7 38563 R111 65.6
R171 32.44 37356 R110 95.5
R120 47.17 37912 187 140
R240 40.3 37635 192 123
R110 26.6 37431 189 82.34
R111 30.8 37451 187 94.8
R167 29 37394 193 88.4
R206 27.8 37595 181 79.5
R222 41.1 38347 174 114.7
R256 39.3 35628 191 119.5
Mean 33.626875 37550.438 R111.75 99.896875
SD 6.8413958 699.85445 5.2141634 20.537952
Min. 21.7 35628 174 61.7

SD, standard deviation.

Ion Reporter has an ontology filter, wherein gene expression, function, and gene families can be used to filter genes. Following our hypothesis, which is based primarily on ion channel genes, we included the following gene ontologies in our analyses: neural, neurological, brain, ion channel, and neuro*. To identify rare and novel mutations, only variants with MAF below 0.001 were included. SIFT and PolyPhen-2, two complementary pathogenicity prediction tools, were used to filter variants in Ion Reporter to ensure that the mutations included were of a certain level of functional impact. It is worth mentioning that only one variant (CACNA1Cp.Ile662Leu) was predicted to be benign by Polyphen, which was reflected by the lowest deleterious prediction score in Table 3a (82%). However, as all other in silico tools predicted this variant to be damaging, it was still included. Each case had an average of 25 filtered variants. The 16 filtered Variant Caller Files (VCFs) were screened for variants in genes in common. However, as none were identified, each case was assessed individually to identify gene variants most likely to contribute to poor response to head trauma as outlined below.

Table 3A.

Predicted Deleteriousness by Several in Silico Tools for the Variants Found in Ion Channel Genes

Case ID Gene Trancript Variant/AA change SIFT PolyPhen PredictSNP2 Mutation Taster Mutation Assessor (FI score)
R170 ATP10A NM_024490.3 c.2642C>T/p.Ala881Val D Probably damaging 87% D D/AA/Protein/SS High (3.98)
R211 ATP7B NM_000053.3 c.2383C>T/p.Leu795Phe D Probably damaging 82% D D/AA/Protein/SS/Known potential disease mutation (HGMD CM970141) Medium (3.35)
R211 CACNA1I NM_021096.3 c.331C>G/p.Arg111Gly D Probably damaging 87% D D/AA/Protein/SS NA
R259 CACNA1C NM_199460.2 c.1984A>C/p.Ile662Leu D B 82% D D/AA/Protein/SS NA
R117 KCNJ10 NM_002R120.4 c.52C>T/p.Arg18Trp D Possibly damaging 87% D D/AA/Protein/SS Medium (2.11)
R118 KCNAB1 NM_172160.2 c.749C>G/p.Ala250Gly D Probably damaging 87% D D/AA/Protein/SS Medium (2.915)
R197 SLC26A4 NM_000441.1 c.412G>A/p.Val138Ile D Probably damaging 87% D D/AA/Protein/SS Medium (3.215)

AA, amino acid; FI, functional impact.

Table 3B.

Predicted Deleteriousness by Several in Silico Tools for the Variants Found in Neurotransmitter Genes

Case ID Gene Transcript Variant/AA change SIFT PolyPhen PredictSNP2 Mutation Taster Mutation Assessor (FI score)
R150 GABRG1 NM_173536.3 c.137A>G/p.Asp46Gly D Probably damaging 87% D D/AA changes/Protein Features/SS changes Medium (2.11)
R171 GRIK1 NM_000830.4 c.1282A>T/p.Asn428Tyr D Probably damaging 87% D D/AA/Protein/SS Medium (3.43)

AA, amino acid; FI, functional impact.

Table 3C.

Predicted Deleteriousness by Several in Silico Tools for the Variants Found in Ubiquitin Genes

Case ID Gene Trancript Variant/AA change SIFT PolyPhen PredictSNP2 Mutation Taster Mutation Assessor (FI score)
R120 TRIM2 NM_015271.3 c.158G>C/p.Cys53Ser D Probably damaging 87% D D/AA/Protein/SS High (4.6)
R240 HECTD1 NM_015382.3 c.5000G>A/p.Arg1667His D Probably damaging 87% D D/AA/Protein/SS Low (1.83)
R110, R111 SQSTM1 NM_003900.4 c.1210A>G/p.Met404Val D Possibly damaging 87% D D/AA/Protein/SS Medium (2.98)

AA, amino acid; FI, functional impact.

Table 3.

A–C. Key

SIFT PolyPhen PredictSNP2 Mutation Taster
T = Tolerated   D = Deleterious D = Disease causing
D = Deleterious     AA changes = Amino acid changes
DL = Deleterious low confidence B = Predicted benign   Protein = Protein feature might be affected
      SS = splice site changes

Rare and novel variants were found in 12 cases, including in genes encoding potassium channels (KCNJ10 and KCNAB1), calcium channels (CACNA1I and CACNA1C), ATPases (ATP10A and ATP7B), Solute Carriers (SLC26A4), and neurotransmitter receptors (GABRG1 and GRIK1). Further, in 4 of the cases, although no relevant variants in ion channel or neurotransmitter genes were found, variants in ubiquitin-related genes (SQSTM1, HECTD1, and TRIM2), which were included as part of the neuronal ontology filter, were detected and are of potential interest. MAFs of each of the identified variants from the databases are summarized in Table 4.

Table 4.

Minor Allele Frequencies (MAFs) of Variants Deemed Relevant to Symptoms by WES Analysis

Case ID Gene Variant gnomAD TOP-MED count
R170 ATP10A rs142704035 19 in 277134 (0.00006) 9
R211 ATP7B rs751710854 7 in 246244 (0.00002)  
R211 CACNA1I rs751729397 4 in R117482 (0.00001)  
R259 CACNA1C chr12:2690844 _  
R117 KCNJ10 rs138457635 97 in 277144 = 0.0003500 61
R118 KCNAB1 No rs 3:156232893 C / G 1 in 239230 (0.000004)  
R197 SLC26A4 rs111033199 44 in 276848 (0.0001) 26
R150 GABRG1 rs759786658 4 in 274046 (0.00001) 2
R171 GRIK1 rs757997768 1 in 246130 (0.000004) 2
R120 TRIM2 No rs chr4:154191614G>C _  
R240 HECTD1 rs371260055 13 in 276216 (0.00004)  
R110, R111 SQSTM1 rs771966860 4 in 246230 (0.00001) 2

WES, whole exome sequencing.

Scores from in silico prediction tools are reported in Table 3 for all the variants. All mutations identified via WES were predicted to be over 80% deleterious by predictSNP2 and predicted to be disease-causing (not a polymorphism) by Mutation Taster. Despite the variation in symptoms among the cases included in this study, the cohort can be categorized into four groups of main symptomatology: migraine, light and noise sensitivity, hemiparesis or hemiplegia, and cerebral edema or stroke. Using an alternative variant explorer (VCF-DART)32 produced results identical to those reached using Ion Reporter. This was assessed via exploring the variants with MAF less than 0.01 and predicted to be deleterious in the gene lists of Supplementary Appendix S1. In the 2 cases where the most relevant variant to the presentation was not in the gene lists, it was identified in the last tier where variants predicted to be highly deleterious in any additional genes are presented.

Of the 7 case patients who developed migraine following minor head injuries, 2 had ATPase-related variants. The variant in ATP10A has a high predicted functional impact and has an MAF of 0.00006, whereas the ATP7B variant has a medium predicted functional impact and has an even lower MAF of 0.00002. In the related (father and son) cases (R110 and R111), a Sequestome 1 (SQSTM1) mutation was identified (MAF = 0.00001). Another case patient, R197, was found to have an SLC26A4 mutation, which is known as a pathogenic variant for Pendred syndrome, according to Human Gene Mutation Database (HGMD) and dbSNP (MAF = 0.0001). Finally, a glutamate receptor mutation (GRIK1), found in case patient R171, was found in one other individual only, in gnomAD (MAF = 0.000004).

There were 2 case patients who developed light and noise sensitivity following their minor head injuries. The first one (R259) had a CACNA1C mutation that is novel. The other case patient (R117) had a mutation in KCNJ10, which has been reported as a variant of uncertain significance for the autosomal recessive Seizures, Sensorineural deafness, and Ataxia, Mental retardation, and Electrolyte imbalance (SeSAME) syndrome and has a slightly higher MAF (0.0003) than the rest of the variants found in this cohort.

A third group presented with cerebral edema and ischemic stroke following head injuries. One case patient had a novel variant in TRIM2, one had a GABRG1 variant with a MAF of 0.00001, and one had a KCNAB1 variant that does not have an assigned reference SNP ID number on dbSNP.

Discussion

In this study, we hypothesized that ion channel and neurotransmitter genes would harbor rare (MAF ≤0.001) deleterious mutations in individuals who developed concussion-related symptoms following mostly trivial head trauma. Among the 16 individuals screened by WES in this study, 12 case patients were identified to have variants predicted to be deleterious in other neuronal genes. Of the latter, deleterious variants either implicated in autosomal recessive neurological disorders or located in genes in which other mutations cause a neurological disorder were observed in 8 of 12 cases. Therefore, we propose that, similar to some CACNA1A and ATP1A2 mutation carriers, individuals with deleterious variants in other neuronal genes, particularly those involved in ion homeostasis, may lead to an increased vulnerability to head trauma. This premise of genetic risk modulating the severity of acquired neurological dysfunction has already been demonstrated in animal models of epilepsy.34 As such, it follows that this hypothesis might also suit the case of neuronal vulnerability to head trauma.

Ion homeostasis genes and pathways

Functional studies of FHM2 (ATP1A2) mutations in transgenic knock-in mice suggest that collectively, causal ion-channel mutations facilitate cortical spreading depression (with similar events implicated in concussion) as a result of defective removal of glutamate by glial cells, causing a similar downstream net effect as seen with FHM1 mutations.35,36 The established involvement of the Na+/K+-ATPase in the processes that follow head trauma as well as other neurological disorders supports our neuronal vulnerability hypothesis, and a potential role for ion channel genes in modulating concussion-related symptoms. In our cohort of individuals with severe response to minor head trauma, we identified variants predicted to be deleterious in genes related to ATPase, calcium and potassium channels, and other solute carriers.

ATPase genes

Two ATPase-related genes, ATP10A and ATP7B, were identified as candidates in our cohort. ATP10A encodes a catalytic component of the P4-ATPase complex, which has a flippase activity influencing lipids in plasma membranes,37 whereas ATP7B encodes copper-binding domains and transmembrane copper transporters.38

Variants in ATP10A, another candidate gene in our cohort, have been found in individuals with autism (which share pathways with migraine,39,40 and Angelman syndrome.41 Russo and colleagues40 suggest that ATP10A imprinting is linked to migraine with aura (MA) through a locus in the 15q11-q13 region. In our study, case patient R170 with an ATP10A variant (p.Ala881Val) presented with a confusional migraine following minor head injury. Although this person might not routinely suffer from migraine, a stressor (head injury) may have triggered the ATP10A risk allele effect.

ATP7B encodes copper-binding domains and transmembrane copper transporters.38 The variant identified in this study in ATP7B (p.Leu795Phe) is located in transmembrane number 4 of the gene and is documented as a likely pathogenic allele for Wilson syndrome, an autosomal recessive copper metabolism disorder.42 Wilson syndrome is characterized by neurological dysfunction as the primary presentation in patients in their 20s and 30s.38 Although it is an autosomal recessive disorder, heterozygote mutations in ATP7B have also been found to affect related symptomatology in carriers.43 In addition, copper ion imbalance has also been linked to migraine and ataxia,44,45 with dysfunctional copper metabolism linked to axonal neuropathy.46 Case patient R211 in this study presented with a severe migraine and ataxia following a head injury, both of which are plausible phenotypes resulting from ATP7B mutations, potentially the result of an extreme stressor such as head trauma.

Calcium channels

Voltage-gated calcium channels have been previously implicated in epilepsy, hemiplegic migraine, and schizophrenia47,48 with extracellular calcium levels influencing neurotransmitter secretion.49 CACNA1A remains the most investigated gene with regard to head trauma response. Mutations in CACNA1A demonstrate heterogenous neurological presentations, as exemplified by a family harboring the same mutation with varying symptomology including migraine, hemiplegia, coma, and progressive cerebellar ataxia.50 A novel CANCA1C (p.Ile662Leu) variant was detected in a case patient (R259) presenting with prolonged migraine attacks and photophobia following a minor hit on the head by a ball while playing a sport (netball). Interestingly, CACNA1C mechanisms have also been implicated in the survival of young neurons in the hippocampus and forebrains of animal models.51 Another case patient (R211) had a predicted deleterious rare variant (p.Arg111Gly) in the CACNA1I voltage-gated calcium channel gene and presented with a severe migraine and ataxia following head injury. CACNA1I has been implicated in neurological disorders as well as arthritis and schizophrenia.52 It should also be noted that this is the same case patient (R211) identified to have an ATP7B mutation, and these variants both may contribute to the response following trauma.

Potassium channels

As discussed earlier, potassium channels play a crucial role in response to head trauma as well as several neurological disorders. We found a rare predicted-deleterious variant in KCNJ10, a gene previously implicated in symptom development and recovery following mTBI.53 KCNJ10 encodes the potassium channel Kir4.1, an inwardly rectifying potassium channel, which restores negative resting potential mediating the clearing of extracellular glutamate.54 The case patient (R117) identified with a KCNJ10 variant (p.Arg18Trp) presented with recurrent episodes of pallor and vomiting following minor head injuries. The patient identified sensitivity to loud noises and was sensitive to light for 3 weeks following the event. Additionally, the case patient's mother was noted to have a history of migraines, but there was no other significant family history of neurological problems. SeSAME-like syndrome has been reported in heterozygous carriers of other missense variants in KCNJ1055 and mutations in this gene have been found to cause epileptic encephalopathy.56

Another potassium channel gene identified with variants in our cohort was KCNAB1, which is strongly transcribed in the dorsolateral prefrontal cortex and encodes the potassium voltage channel Kv1.57 In this study, the case patient (R118) with a variant in KCNAB1 (p.Ala250Gly) suffered catastrophic cerebral edema following a trivial injury. It is worth noting that KCNAB1 is downregulated in peri-hematomal areas in the brain following hemorrhages, which usually leads to edema and secondary injuries.58 Hence, changes in potassium Kv1 voltage channel function due to an AA changing variant in KCNAB1 may have contributed to the immediate neurological aftermath of the head injury.

Neurotransmitters

Neurotransmission is essential to neuronal ion channel functioning, controlling excitability and inhibition based on the efflux and influx of neurotransmitters. Head injuries cause changes to neurotransmitter expression, which include but not limited to the gamma-aminobutyric acid (GABA)59,60 and glutamate61 receptors that perform a neuroprotective role in response to head injury.62

Neurotransmitters are disrupted following impact, during seizures and migraines and suppression of the GABA receptor subtype A is linked to post-stroke neuronal damage and ischemic death.63 Potentially pathogenic variants in genes involved in neurotransmitter pathways, GABRG1 and GRIK1, were found in 2 cases in this study. GABA type-A receptor gamma1 subunit (GABRG1) encodes a protein that is part of the heteromeric pentameric ligand-gated ion channel family, highly expressed in the brain.64 Mutations in this gene have been implicated in epilepsy and seizure cases65 as well as in the aftermath of brain injuries, where significant changes in neurotransmitter GABA-related gene expression has been documented.59 In addition, GABA agonists have been found to protect against ischemia following injury.63 The case patient (R150) with a GABRG1 variant (p.Asp46Gly) had developed an ischemic stroke following a mild head injury, which may indicate that any neuroprotective function conferred by GABRG1 was impaired.

Another neurotransmitter, glutamate, whose levels rise dramatically following impact or stroke, is hypothesized to play a role in the aftermath of TBI. In particular, indiscriminate glutamate release leads to increased intracellular Ca2+ following concussion.61 Glutamate is also believed to contribute to secondary injuries through excitotoxicity.66 The GRIK1 gene encodes an N-methyl-D-aspartate (NMDA) receptor and has been implicated in epilepsy-related neurological disorders67 as well as in migraine pathogenesis.68 The latter finding is compatible with the presentation of the case (R171) in which a GRIK1 (p.Asn428Tyr) predicted deleterious variant was identified following the development of a confusional migraine after a minor head injury. With the principal of neuroprotection depending on a balance between excitatory (e.g., glutamate) and inhibitory (e.g., GABA) neurotransmitters,69 it follows that impairment of glutamate and GABA receptors may alter this balance and posit neurons at risk following stress (e.g., trauma).

The SLC26A4 variant (p.Val138Ile) that we identified in case R197 is a variant reported to cause Pendred syndrome, an autosomal recessive disorder characterized by vestibular migraines as common comorbidity70 due to enlarged vestibular aqueducts and associated sensorineural dysfunctions.71 Interestingly, a case patient (R197) developed a migraine following minimal trauma and confusion and headache post rugby games, which may have provided a trigger if the patient was vulnerable from a deleterious allele.

Ubiquitin genes

Sequestome 1 (SQSTM1) is the ubiquitin-binding protein p62, and mutations in this gene are implicated in frontotemporal dementia (FTD) and or amyotrophic lateral sclerosis (ALS).72–75 Several studies have identified that the mechanism with which p62 deficiency contributes to neuropathology is via impairment of complex 1 mitochondrial respiration.76,77 SQSTM1 mutations have also been implicated in neurodegeneration with ataxia, dystonia, and gaze palsy, mostly linked to autophagy, and mitophagy in particular.78,79 The predicted pathogenic variant SQSTM1 (p. Met404Val) was observed to be present in both a father (R111) and a son (R110) with a similar presentation, wherein after minor head trauma, both developed “migraine-like” episodes, with slurred speech, diplopia, headache, and vomiting. These neurological disturbances seem to overlap with those from the heterogeneous set of disorders implicating this gene. In particular, the proposed impairment of mitochondrial respiration could exacerbate neuronal oxidative stress following head trauma resulting in these episodes.

The TRIM2 gene has a neuroprotective role and is an E3-ubiquitin ligase in proteasome-mediated degradation of target proteins. Loss of function mutations in this gene have been implicated in early-onset axonal neuropathy,80 and Charcot-Marie-Tooth autosomal recessive disorder.81 Thompson and colleagues82 demonstrated that TRIM2 ubiquitination of a cell death mediator (Bim/Bcl-2) is one pathway for neuroprotection, and suppressing expression of TRIM2 blocked this ubiquitination and any neuroprotective processes.

Further, Boone and colleagues83 found that TRIM2 expression is suppressed in dying hippocampal cells following TBI. In this study, case patient R120 suffered severe bleeding following a minor fall, causing malignant edema and subdural bleeding. Impairment of the ubiquitin-proteasome system is implicated in neurodegeneration,84 with evidence from animal models of compromised TRIM2 brain expression resulting in axonal swelling, accumulation of disorganized neurofilaments, and the formation of microtubules.85 Thus, we propose that a heterozygote mutation affecting the integrity of TRIM2 ubiquitination properties might be exacerbated in the aftermath of an external trigger (fall). HECTD1, like TRIM2, is an E3-ubiquitin ligase, with mutations implicated in autism spectrum disorders and neurodegeneration. HECTD1 plays a role in the development of the head mesenchyme and neural tube closure86 with mutations in this gene linked to neural tube defects.87 Case patient R240 with the identified HECTD1 variant presented with confusion and headache following a minor head injury (netball).

It is not surprising that numerous genes in this study identified as candidates in response to head trauma are implicated in neurodegeneration.88 In a review by Sundman and colleagues,89 the occurrence of ALS in patients with mTBI was explored, finding higher odds ratios in cases of prior head trauma, suggesting a possible link. Here, we add to this hypothesis by proposing that neural vulnerability may involve a shared vulnerability to head trauma through neurodegeneration risk.

Limitations

We acknowledge our lack of access to family members for this study, thus limiting our ability to establish these mutations as candidate causal variants. Further, the individuals examined in this study were referred specifically for suspected FHM symptoms. Hence, we acknowledge the heterogeneity of their presentations and we are unable to make any conclusions of susceptibility beyond our neuronal vulnerability hypothesis, which needs to be explored in larger cohorts of patients with mTBI and concussion. We also acknowledge the varied range of age in our population, and due to the sample size, it is difficult to determine if age at injury has any effect of variant pathogenicity. Our analysis targeted the inclusion of genes with neuronal-related ontology, and variants with a low MAF and high deleterious effect prediction scores from in silico prediction tools. Although this approach potentially leads to identifying variants with high penetrance, other more common, less deleterious variants potentially contribute to individual etiology.

Conclusion

We have found rare and predicted-to-be-damaging variants in ion channel and neurotransmitter-related genes in addition to CACNA1A and ATP1A2, in individuals with severe responses to minor head trauma, implicating them in vulnerability to head trauma. These variants may cause functional changes to neurons, changing the influx of ions or efflux of neurotransmitters. Consequently, we hypothesize that although a heterozygote mutation does not lead to neurological symptoms under normal conditions, head trauma may act as a precipitant of disturbance. Therefore, concussion-related or migraine symptoms could develop in response to a disturbance precipitated by a head impact or trivial trauma in individuals who harbor heterozygous variants that cause autosomal recessive neurological disorders. As the evidence for ion channel involvement in head trauma increases, larger affected cohorts are required to be recruited and examined to confirm the relevance of each gene to specific symptoms subsets.

Supplementary Material

Supplemental data
Supp_Appendix1.pdf (27.4KB, pdf)

Acknowledgments

We thank the collaborating clinicians for their referrals and the research participants for their time and contributions.

Data accessibility

Sequencing data are available upon request, subject to the data sharing and transfer agreements of respective institutions.

Funding Information

We acknowledge funding support from the US Department of Defence for Post Traumatic Headache Research and funding provided by QUT Health Faculty in the form of a PhD scholarship to the first author. This work was also supported by infrastructure purchased with Australian Government EIF Super Science Funds as part of the Therapeutic Innovation Australia - Queensland Node project.

Author Disclosure Statement

No competing financial interests exist.

Supplementary Material

Supplementary Appendix S1

References

  • 1. Mazzo F., Zwart R. S erratto G.M., Gardinier K.M., Porter W., Reel J., Maraula G., and Sher E. (2016). Reconstitution of synaptic Ion channels from rodent and human brain in Xenopus oocytes: a biochemical and electrophysiological characterization. J. Neurochem. 138, 384–396 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Stiefel M.F., YTomita Y., and Marmarou A. (2005). Secondary ischemia impairing the restoration of ion homeostasis following traumatic brain injury. J. Neurosurg. 103, 707–714 [DOI] [PubMed] [Google Scholar]
  • 3. Maksemous N., Roy B., Smith R.A., and Griffiths L.R. (2016). Next-generation sequencing identifies novel CACNA1A gene mutations in episodic ataxia type 2. Mol. Genet. Genomic Med. 4, 211–222 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Kors E.E., Terwindt G.M., Vermeulen F.L., Fitzsimons R.B., Jardine P.E. Heywood P., Love S., Van Den Maagdenberg A.M., Haan J., and Frants R.R. (2001). Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann.Neurol. 49, 753–760 [DOI] [PubMed] [Google Scholar]
  • 5. Terwindt G., and van den Maagdenberg A. (2009). Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation. J. Neurol. Neurosurg. Psychiatry, 80, 1125–1129 [DOI] [PubMed] [Google Scholar]
  • 6. Pelzer N., Blom D., Stam A., Vijfhuizen L., Hageman A., van Vliet J., Ferrari M., van den Maagdenberg A., Haan J., and Terwindt G. (2017). Recurrent coma and fever in familial hemiplegic migraine type 2. A prospective 15-year follow-up of a large family with a novel ATP1A2 mutation. Cephalalgia 37, 737–755 [DOI] [PubMed] [Google Scholar]
  • 7. Maksemous N., Smith R.A., Sutherland H.G., Maher B.H., Ibrahim O., Nicholson G.A., Carpenter E.P., Lea R.A., Cader M.Z., and Griffiths L.R. (2019). Targeted next generation sequencing identifies a genetic spectrum of DNA variants in patients with hemiplegic migraine. Cephalalgia Rep. 2, 2515816319881630 [Google Scholar]
  • 8. Raymond G.V., Seidman R., Monteith T.S., Kolodny E., Sathe S., Mahmood A., and Powers J.M. (2010). Head trauma can initiate the onset of adreno-leukodystrophy. J. Neurol. Sci. 290, 70–74 [DOI] [PubMed] [Google Scholar]
  • 9. Curtain R.P., Smith R.L., Ovcaric M., and Griffiths L.R. (2006). Minor head trauma-induced sporadic hemiplegic migraine coma. Pediatr. Neurol. 34, 329–332 [DOI] [PubMed] [Google Scholar]
  • 10. Berkovic S.F., Mulley J.C., Scheffer I.E., and Petrou S. (2006). Human epilepsies: interaction of genetic and acquired factors. Trends Neurosci. 29, 391–397 [DOI] [PubMed] [Google Scholar]
  • 11. Walter A., Herrold A.A., Gallagher V.T., Lee R., Scaramuzzo M., Bream T., Seidenberg P.H., Vandenbergh D., O'Connor K., Talavage T.M., Nauman E.A., Slobounov S.M., and Breiter H.C. (2019). KIAA0319 genotype predicts the number of past concussions in a division I football team: a pilot study. J. Neurotrauma 36, 1115–1124 [DOI] [PubMed] [Google Scholar]
  • 12. Niechwiej-Szwedo E., Gonzalez D., Tapper A., Mardian E., Roy E., and Duncan R. (2015). The BDNF Val66Met polymorphism is associated with improved performance on a visual-auditory working memory task in varsity athletes. J. Vision 15, 676–676
  • 13. Narayanan V., Veeramuthu V. A hmad-Annuar A., Ramli N., Waran V., Chinna K., Bondi M.W., Delano-Wood L., and Ganesan D. (2016). Missense mutation of brain derived neurotrophic factor (BDNF) alters neurocognitive performance in patients with mild traumatic brain injury: a longitudinal study. PLoS One 11, e0158838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Larson-Dupuis C., Chamard E., Falardeau V., Frasnelli J., Beaulieu C., Poirier J., Carrier J., Lassonde M., Théoret H., Bacon B.-A., and De Beaumont L. (2015). Impact of BDNF Val66Met polymorphism on olfactory functions of female concussed athletes. Brain Inj. 29, 963–970 [DOI] [PubMed] [Google Scholar]
  • 15. Terrell T.R., Bostick R.M., Abramson R., Xie D., Barfield W., Cantu R., Stanek M., and Ewing T. (2008). APOE, APOE promoter, and tau genotypes and risk for concussion in college athletes. Clin. J. Sport Med. 18, 10–17 [DOI] [PubMed] [Google Scholar]
  • 16. Yue J., Robinson C.K., Burke J.F., Winkler E.A., Deng H., Cnossen M., Lingsma H., Ferguson A., McAllister T.W., Rosand J. B urchard E., Sorani M., Sharma S., Nielson J.L. Satris G.G., Talbott J.F., Tarapore P.E., Korley F.K., Wang K.K.W., Yuh E., Mukherjee P., Diaz-Arrastia R., Valadka A., Okonkwo D., Manley G., and TRACK-TBI Investigators. (2017). Apolipoprotein E epsilon 4 (APOE-ɛ4) genotype is associated with decreased 6-month verbal memory performance after mild traumatic brain injury. Brain Behav. 7, e000791., [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Meaney D.F., and Smith D.H. (2011). Biomechanics of concussion. Clin. Sports Med. 30, 19–31 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Finnoff J.T., Jelsing E.J., and Smith J. (2011). Biomarkers, genetics, and risk factors for concussion. PM R 3, S452–S459 [DOI] [PubMed] [Google Scholar]
  • 19. Giza C.C., and Hovda D.A. (2014). The new neurometabolic cascade of concussion. Neurosurg..75, Suppl. 4, S24–S33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Bergsneider M., Hovda D.A., Shalmon E., Kelly D.F., Vespa P.M., Martin N.A., Phelps M.E., McArthur D.L., Caron M.J., Kraus J.F., and Becker D.P. (1997). Cerebral hyperglycolysis following severe traumatic brain injury in humans: a positron emission tomography study. J. Neurosurg. 86, 241–251 [DOI] [PubMed] [Google Scholar]
  • 21. Gurkoff G., Shahlaie K., Lyeth B., and Berman R. (2013). Voltage-gated calcium channel antagonists and traumatic brain injury. Pharmaceuticals 6, 788–812 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Finkel A.G., Yerry J.A., Klaric J.S., Ivins B.J., Scher A., and Choi Y.S. (2017). Headache in military service members with a history of mild traumatic brain injury: a cohort study of diagnosis and classification. Cephalalgia 37, 548–559 [DOI] [PubMed] [Google Scholar]
  • 23. Stam A.H., Luijckx G.-J., Poll-Thé B.T., Ginjaar I.B., Frants R.R., Haan J., Ferrari M.D., Terwindt G.M., and van den Maagdenberg A.M.JM. (2009). Early seizures and cerebral oedema after trivial head trauma associated with the CACNA1A S218L mutation. J. Neurol. Neurosurg. Psychiatry 80, 1125–1129 [DOI] [PubMed] [Google Scholar]
  • 24. Blumkin L., Michelson M., Leshinsky-Silver E., Kivity S., Lev D., and Lerman-Sagie T. (2010). Congenital ataxia, mental retardation, and dyskinesia associated with a novel CACNA1A mutation. J. Child Neurol. 25, 892–897 [DOI] [PubMed] [Google Scholar]
  • 25. Van Maagdenberg A.M., Pizzorusso T., Kaja S., Terpolilli N., Shapovalova M., Hoebeek F.E., Barrett C.F., Gherardini L., van de Ven R.C., Todorov B., Broos L.A., Tottene A., Gao Z., Fodor M., de Zeeuw C.I., Frants R.R., Plesnila N., Plomp J.J., Pietrobon D., and Ferrari M.D. (2010). High cortical spreading depression susceptibility and migraine-associated symptoms in Ca(v)2.1 S218L mice. Ann. Neurol. 67, 85–98 [DOI] [PubMed] [Google Scholar]
  • 26. Radhakrishnan R., Garakani A., Gross L.S., Goin M.K., Pine J., Slaby A.E., Sumner C.R., and Baron D.A. (2016). Neuropsychiatric aspects of concussion. Lancet Psychiatry 3, 1166–1175 [DOI] [PubMed] [Google Scholar]
  • 27. Flanagan S.E., Patch A.-M., and Ellard S. (2010). Using SIFT and PolyPhen to predict loss-of-function and gain-of-function mutations. Genet. Test Mol. Biomarkers 14, 533–537 [DOI] [PubMed] [Google Scholar]
  • 28. Korvigo I., Afanasyev A., Romashchenko N., and Skoblov M. (2018). Generalising better: applying deep learning to integrate deleteriousness prediction scores for whole-exome SNV studies. PLoS One 13, e0192829. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Reva B., Antipin Y., and Sander C. (2011). Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39, e118–e118 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Glass K., and Girvan M. (2014). Annotation enrichment analysis: an alternative method for evaluating the functional properties of gene sets. Sci. Rep. 4, 4191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Schwarz J.M., Rödelsperger C., Schuelke M., and Seelow D. (2010). MutationTaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7, 575. [DOI] [PubMed] [Google Scholar]
  • 32. Benton M.C., Smith R.A., Haupt L.M., Sutherland H.G., Dunn P.J., Albury C.L., Maksemous N., Lea R., and Griffiths L. (2019). Variant Call Format–Diagnostic Annotation and Reporting Tool: A Customizable Analysis Pipeline for Identification of Clinically Relevant Genetic Variants in Next-Generation Sequencing Data. J. Mol. Diagn. 21, 951–960 [DOI] [PubMed]
  • 33. Carson A.R., Smith E.N., Matsui H., Brækkan S.K., Jepsen K., Hansen J.-B., and Frazer K.A. (2014). Effective filtering strategies to improve data quality from population-based whole exome sequencing studies. BMC Bioinformatics 15, 125–125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Frankel W.N., Taylor L., Beyer B., Tempel B.L., and White H.S. (2001). Electroconvulsive thresholds of inbred mouse strains. Genomics 74, 306–312 [DOI] [PubMed] [Google Scholar]
  • 35. Bottger P., Glerup S., Gesslein B., Illarionova N.B., Isaksen T.J., Heuck A., Clausen B.H., Fuchtbauer E.M., Gramsbergen J.B., Gunnarson E., Aperia A., Lauritzen M., Lambertsen K.L., Nissen P., and Lykke-Hartmann K. (2016). Glutamate-system defects behind psychiatric manifestations in a familial hemiplegic migraine type 2 disease-mutation mouse model. Sci. Rep. 6, 22047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Leo L., Gherardini L., Barone V., De Fusco M., Pietrobon D., Pizzorusso T., and Casari G. (2011). Increased susceptibility to cortical spreading depression in the mouse model of familial hemiplegic migraine type 2. PLoS Genet. 7, e1002129. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Naito T., Takatsu H., Miyano R., Takada N., Nakayama K., and Shin H.W. (2015). Phospholipid flippase ATP10A translocates phosphatidylcholine and is involved in plasma membrane dynamics. J. Biol. Chem. 290, 15004–15017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Machado A.A.C., Deguti M.M., Genschel J., Cançado E.L.R., Bochow B., Schmidt H., and Barbosa E.R. (2008). Neurological manifestations and ATP7B mutations in Wilson's disease. Parkinsonism Relat. Disord. 14, 246–249 [DOI] [PubMed] [Google Scholar]
  • 39. Schmunk G., and Gargus J.J. (2013). Channelopathy pathogenesis in autism spectrum disorders. Front. Genet. 4, 222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Russo L., Mariotti P., Sangiorgi E., Giordano T., Ricci I., Lupi F., Chiera R., Guzzetta F., Neri G., and Gurrieri F. (2005). A new susceptibility locus for migraine with aura in the 15q11-q13 genomic region containing three GABA-A receptor genes. Am. J. Hum. Genet. 76, 327–333 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Gargus J.J. (2009). Genetic calcium signaling abnormalities in the central nervous system: seizures, migraine, and autism. Ann. N Y Acad. Sci. 1151, 133–156 [DOI] [PubMed] [Google Scholar]
  • 42. Aggarwal A., Chandhok G., Todorov T., Parekh S., Tilve S., Zibert A., Bhatt M., and Schmidt H.H. (2013). Wilson disease mutation pattern with genotype-phenotype correlations from Western India: confirmation of p.C271* as a common Indian mutation and identification of 14 novel mutations. Ann. Hum. Genet. 77, 299–307 [DOI] [PubMed] [Google Scholar]
  • 43. Peña-Quintana L., García-Luzardo M.R., García-Villarreal L., Arias-Santos M.D., Garay-Sánchez P., Santana A., González-Santana D., Ramos-Varela J.C., Rial-González R., and Tugores A. (2012). Manifestations and evolution of wilson disease in pediatric patients carrying ATP7B mutation L708P. J. Pediatr. Gastroenterol. Nutr. 54, 48–54 [DOI] [PubMed] [Google Scholar]
  • 44. Borkum J.M. (2016).Migraine triggers and oxidative stress: a narrative review and synthesis. Headache 56, 12–35 [DOI] [PubMed]
  • 45. Dhillon K.S., Singh J., and Lyall J.S. (2011). A new horizon into the pathobiology, etiology and treatment of migraine. Med. Hypotheses 77, 147–151 [DOI] [PubMed] [Google Scholar]
  • 46. Bandmann O., Weiss K.H., and Kaler S.G. (2015). Wilson's disease and other neurological copper disorders. Lancet Neurol. 14, 103–113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Zamponi G.W. (2016). Targeting voltage-gated calcium channels in neurological and psychiatric diseases. Nat. Rev. Drug Discov. 15, 19. [DOI] [PubMed] [Google Scholar]
  • 48. Zhuchenko O., Bailey J., Bonnen P., Ashizawa T., Stockton D.W., Amos C., Dobyns W.B., Subramony S., Zoghbi H.Y., and Lee C.C. (1997). Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel. Nat. Genet. 15, 62. [DOI] [PubMed] [Google Scholar]
  • 49. Petersen O.H., Michalak M., and Verkhratsky A. (2005). Calcium signalling: past, present and future. Cell Calcium 38, 161–169 [DOI] [PubMed] [Google Scholar]
  • 50. Wada T., Kobayashi N., Takahashi Y., Aoki T., Watanabe T., and Saitoh S. (2002). Wide clinical variability in a family with a CACNA1A T666m mutation: hemiplegic migraine, coma, and progressive ataxia. Pediatr. Neurol. 26, 47–50 [DOI] [PubMed] [Google Scholar]
  • 51. De Jesús-Cortés H., Rajadhyaksha A.M., and Pieper A.A. (2016). Cacna1c: protecting young hippocampal neurons in the adult brain. Neurogenesis 3, e1231160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52. Xie Y., Huang D., Wei L., and Luo X.-J. (2018). Further evidence for the genetic association between CACNA1I and schizophrenia. Hereditas 155, 16–16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Mendez-Gonzalez M.P., Kucheryavykh Y.V., Zayas-Santiago A., Velez-Carrasco W., Maldonado-Martinez G., Cubano L.A., Nichols C.G., Skatchkov S.N., and Eaton M.J. (2016). Novel KCNJ10 Gene variations compromise function of inwardly rectifying potassium channel 4.1. J. Biol. Chem. 291, 7716–7726 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Inyushin M., Kucheryavykh L.Y., Kucheryavykh Y.V., Nichols C.G., Buono R.J., Ferraro T.N., Skatchkov S.N., and Eaton M.J. (2010). Potassium channel activity and glutamate uptake are impaired in astrocytes of seizure susceptible DBA/2 mice. Epilepsia 51, 1707–1713 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Sala-Rabanal M., Kucheryavykh L.Y., Skatchkov S.N., Eaton M.J., and Nichols C.G. (2010). Molecular mechanisms of EAST/SeSAME syndrome mutations in Kir4.1 (KCNJ10). J. Biol. Chem. 285, 36040–36048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56. Zhang Y., Kong W., Gao Y., Liu X., Gao K., Xie H., Wu Y., Zhang Y., Wang J., Gao F., Wu X., and Jiang Y. (2015). Gene mutation analysis in 253 Chinese children with unexplained epilepsy and intellectual/developmental disabilities. PLoS One 10, e0141782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Busolin G., Malacrida S., Bisulli F., Striano P., Di Bonaventura C., Egeo G., Pasini E., Cianci V., Ferlazzo E., Bianchi A., Coppola G., Elia M., Mecarelli O., Gobbi G., Casellato S., Marchini M., Binelli S., Freri E., Granata T., Posar A., Parmeggiani A., Vigliano P., Boniver C., Aguglia U., Striano S., Tinuper P., Giallonardo A.T., Michelucci R., and Nobile C. (2011). Association of intronic variants of the KCNAB1 gene with lateral temporal epilepsy. Epilepsy Res. 94, 110–116 [DOI] [PubMed] [Google Scholar]
  • 58. Rosell A., Vilalta A., García-Berrocoso T., Fernández-Cadenas I., Domingues-Montanari S., Cuadrado E., Delgado P., Ribó M., Martínez-Sáez E., Ortega-Aznar A., and Montaner J. (2011). Brain perihematoma genomic profile following spontaneous human intracerebral hemorrhage. PLoS One 6, e16750. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. Gibson C.J., Meyer R.C., and Hamm R.J. (2010). Traumatic brain injury and the effects of diazepam, diltiazem, and MK-801 on GABA-A receptor subunit expression in rat hippocampus. J. Biomed. Sci. 17, 38–38 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Drexel M., Puhakka N., Kirchmair E., Hörtnagl H., Pitkänen A., and Sperk G. (2015). Expression of GABA receptor subunits in the hippocampus and thalamus after experimental traumatic brain injury. Neuropharmacology 88, 122–133 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61. Guerriero R.M., Giza C.C., and Rotenberg A. (2015). Glutamate and GABA Imbalance following traumatic brain injury. Curr. Neurol. Neurosci. Rep. 15, 1–11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Leonelli M., Torrao A.S., and Britto L.R. (2009). Unconventional neurotransmitters, neurodegeneration and neuroprotection. Braz. J. Med. Biol. Res. 42, 68–75 [DOI] [PubMed] [Google Scholar]
  • 63. Liu, B., Li, L. Zhang, Q. Chang, N. Wang, D. Shan, Y. Li, L. Wang, H. Feng, H. and Zhang, L. (2010). Preservation of GABAA receptor function by PTEN inhibition protects against neuronal death in ischemic stroke. Stroke 41, 1018–1026 [DOI] [PubMed]
  • 64. Fagerberg L., Hallstrom B.M., Oksvold P., Kampf C., Djureinovic D., Odeberg J., Habuka M., Tahmasebpoor S., Danielsson A., Edlund K., Asplund A., Sjostedt E., Lundberg E., Szigyarto C.A., Skogs M., Takanen J.O., Berling H., Tegel H., Mulder J., Nilsson P., Schwenk J.M., Lindskog C., Danielsson F., Mardinoglu A., Sivertsson A., von Feilitzen K., Forsberg M., Zwahlen M., Olsson I., Navani S., Huss M., Nielsen J., Ponten F., and Uhlen M. (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell Proteomics 13, 397–406 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Yuan H., Low C.M., Moody O.A., Jenkins A., and Traynelis S.F. (2015). Ionotropic GABA and glutamate receptor mutations and human neurologic diseases. Mol. Pharmacol. 88, 203–217 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66. Chodobski A., Zink B.J., and Szmydynger-Chodobska J. (2011). Blood–brain barrier pathophysiology in traumatic brain injury. Transl. Stroke Res. 2, 492–516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Wang J., Lin Z.-J., Liu L., Xu H.-Q., Shi Y.-W., Yi Y.-H., He N., and Liao W.-P. (2017). Epilepsy-associated genes. Seizure 44, 11–20 [DOI] [PubMed] [Google Scholar]
  • 68. Vikelis M., and Mitsikostas D.D. (2007). The role of glutamate and its receptors in migraine. CNS Neurol. Disord. Drug Targets 6, 251–257 [DOI] [PubMed] [Google Scholar]
  • 69. Xu J., Liu Y., and Zhang G.-Y. (2008). Neuroprotection of GluR5-containing kainate receptor activation against ischemic brain injury through decreasing tyrosine phosphorylation of N-Methyl-d-aspartate receptors mediated by Src kinase. J. Biol. Chem. 283, 29355–29366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70. Frejo L., Giegling I., Teggi R., Lopez-Escamez J.A., and Rujescu D. (2016). Genetics of vestibular disorders: pathophysiological insights. J. Neurol. 263, 45–53 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Reyes S., Wang G., Ouyang X., Han B., Du L.L., Yuan H.J., Yan D., Dai P., and Liu X.Z. (2009). Mutation analysis of SLC26A4 in mainland Chinese patients with enlarged vestibular aqueduct. Otolaryngol. Head Neck Surg. 141, 502–508 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Van Der Zee J., Van Langenhove T., Kovacs G.G., Dillen L., Deschamps W., Engelborghs S., Matěj R., Vandenbulcke M., Sieben A., and Dermaut B. (2014). Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. Acta neuropathol. 128, 397–410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Rubino E., Rainero I., Chiò A., Rogaeva E., Galimberti D., Fenoglio P., Grinberg Y., Isaia G., Calvo A., and Gentile S. (2012). SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurol. 79, 1556–1562 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Rea S.L., Majcher V., Searle M.S., and Layfield R. (2014). SQSTM1 mutations–bridging Paget disease of bone and ALS/FTLD. Exp. Cell Res. 325, 27–37 [DOI] [PubMed] [Google Scholar]
  • 75. Le Ber I., Camuzat A. G uerreiro R., Bouya-Ahmed K., Bras J., Nicolas G., Gabelle A., Didic M., De Septenville A., and Millecamps S. (2013). SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 70, 1403–1410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Seibenhener M.L., Du Y., Diaz-Meco M.-T., Moscat J., Wooten M.C., and Wooten M.W. (2013). A role for Sequestosome1/p62 in mitochondrial dynamics, import and genome integrity. Biochimica et biophysica acta. 1833, 452–459 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Bartolome F., Esteras N., Martin-Requero A., Boutoleau-Bretonniere C., Vercelletto M., Gabelle A., Le Ber I., Honda T., Dinkova-Kostova A.T., Hardy J., Carro E., and Abramov A.Y. (2017). Pathogenic p62/SQSTM1 mutations impair energy metabolism through limitation of mitochondrial substrates. Sci. Rep. 7, 1666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78. Narendra D., Kane L.A., Hauser D.N., Fearnley I.M., and Youle R.J. (2010). p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 6, 1090–106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79. East D.A., Fagiani F., Crosby J., Georgakopoulos N.D., Bertrand H., Schaap M., Fowkes A., Wells G., and Campanella M. (2014). PMI: a DeltaPsim independent pharmacological regulator of mitophagy. Chem. Biol. 21, 1585–1596 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80. Ylikallio E., Pöyhönen R., Zimon M., De Vriendt E., Hilander T., Paetau A., Jordanova A., Lönnqvist T., and Tyynismaa H. (2013). Deficiency of the E3 ubiquitin ligase TRIM2 in early-onset axonal neuropathy. Hum. Mol. Genet. 22, 2975–2983 [DOI] [PubMed] [Google Scholar]
  • 81. Pehlivan D., Akdemir Z.C., Karaca E., Bayram Y., Jhangiani S., Yildiz E.P., Muzny D., Uluc K., Gibbs R.A., and Elcioglu N. (2015). Exome sequencing reveals homozygous TRIM2 mutation in a patient with early onset CMT and bilateral vocal cord paralysis. Hum. Genet. 134, 671–673 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82. Thompson S., Pearson A.N., Ashley M.D., Jessick V., Murphy B., Gafken P., Henshall D.C., Morris K.T., Simon R.P., and Meller R. (2011). Identification of a novel BIM (BCL-2 interacting mediator of cell death) E3-ligase, tri-partite motif containing protein 2 (TRIM2), and its role in rapid ischemic tolerance-induced neuroprotection. J. Biol. Chem. 286, 19331–19339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83. Boone D.K., Weisz H.A., Bi M., Falduto M.T., Torres K.E., Willey H.E., Volsko C.M., Kumar A.M., Micci M.-A., and Dewitt D.S. (2017).Evidence linking microRNA suppression of essential prosurvival genes with hippocampal cell death after traumatic brain injury. Sci. Rep. 7, 6645 [DOI] [PMC free article] [PubMed]
  • 84. McKinnon C., and Tabrizi S.J. (2014). The ubiquitin-proteasome system in neurodegeneration. Antioxid. Redox. Signal. 21, 2302–2321 [DOI] [PubMed] [Google Scholar]
  • 85. Balastik M., Ferraguti F., Pires-da Silva A., Lee T.H., Alvarez-Bolado G., Lu K.P., and Gruss P. (2008). Deficiency in ubiquitin ligase TRIM2 causes accumulation of neurofilament light chain and neurodegeneration. Proc. Natl. Acad. Sci. U S A 105, 12016–12021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86. Yamaguchi Y., and Miura M. (2013). How to form and close the brain: insight into the mechanism of cranial neural tube closure in mammals. Cell. Mol. Life Sci. 70, 3171–3186 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87. Greene N.D., Stanier P., and Copp A.J. (2009). Genetics of human neural tube defects. Hum. Mol. Genet. 18, R113–R129 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88. Muto V., Flex E., Kupchinsky Z., Primiano G., Galehdari H., Dehghani M., Cecchetti S., Carpentieri G., Rizza T., Mazaheri N., Sedaghat A., Mehrjardi M.Y.V., Traversa A., Di Nottia M., Kousi M.M., Jamshidi Y., Ciolfi A., Caputo V., Malamiri R.A., Pantaleoni F., Martinelli S., Jeffries A.R., Zeighami J., Sherafat A., Di Giuda D., Shariati G.R., Carrozzo R., Katsanis N., Maroofian R., Servidei S., and Tartaglia M. (2018). Biallelic SQSTM1 mutations in early-onset, variably progressive neurodegeneration. Neurology 91, e319–e330 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89. Sundman M.H., Hall E.E., and Chen N.K. (2014). Examining the relationship between head trauma and neurodegenerative disease: a review of epidemiology, pathology and neuroimaging techniques. J. Alzheimers Dis. Parkinsonism 4. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental data
Supp_Appendix1.pdf (27.4KB, pdf)

Data Availability Statement

Sequencing data are available upon request, subject to the data sharing and transfer agreements of respective institutions.


Articles from Journal of Neurotrauma are provided here courtesy of Mary Ann Liebert, Inc.

RESOURCES